COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

NCT ID: NCT03667716

Last Updated: 2025-01-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 121 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-06
• Study Completion Date: 2024-01-30

Brief Summary

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.

Detailed Description

This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with nivolumab in subjects with advanced solid tumors. Cohort expansion will be explored evaluating COM701 monotherapy and in combination with nivolumab in subjects with the following select tumor types (Non-Small cell lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and endometrial cancer. Other tumor types such as CRC-MSS, CRC-KRAS mutant will be enrolled based on emerging clinical activity data.

Conditions

Advanced Cancer; Ovarian Cancer; Breast Cancer; Lung Cancer; Endometrial Cancer; Ovarian Neoplasm; Triple Negative Breast Cancer; Lung Neoplasm; Neoplasm Malignant; Colo-rectal Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

P1b (Combination Cohort Dose Expansion).

COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).

Group Type: EXPERIMENTAL

COM701 with Opdivo (Nivolumab).

Intervention Type: DRUG

COM701 in combination with Opdivo (Nivolumab).

P1a Arm A (Monotherapy Dose Escalation).

COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.

Group Type: EXPERIMENTAL

COM701

Intervention Type: DRUG

COM701 monotherapy.

P1a Arm B (Combination Dose Escalation).

COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.

Group Type: EXPERIMENTAL

COM701 with Opdivo (Nivolumab).

Intervention Type: DRUG

COM701 in combination with Opdivo (Nivolumab).

P1a Arm A (Monotherapy Expansion).

COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).

Group Type: EXPERIMENTAL

COM701

Intervention Type: DRUG

COM701 monotherapy.

Interventions

COM701

COM701 monotherapy.

Intervention Type: DRUG

COM701 with Opdivo (Nivolumab).

COM701 in combination with Opdivo (Nivolumab).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Subjects who received prior immune-stimulatory antitumor agents, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, OX-40, CD137, etc. are eligible.
• Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all the available standard therapy or is not a candidate for the available standard therapy.

Select Tumor Types (COM701 monotherapy cohort expansion; COM701 in combination with nivolumab):

• Breast cancer (TNBC): Histologically confirmed incurable, advanced estrogen receptor-, progesterone receptor-, and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) adenocarcinoma of the breast, as defined by the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines. Disease recurrence or progression during or after at least one systemic treatment that included an anthracycline and/or a taxane in the neoadjuvant, adjuvant, or metastatic setting. Subjects must have progressed after a poly ADP-ribose polymerase (PARP) inhibitor for patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutated metastatic breast cancer. P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort.
• Endometrial cancer: Subjects with locally advanced or metastatic endometrial cancer, disease recurrence or progression during or after prior therapy that included platinum-based chemotherapy. P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort.
• Ovarian cancer: Disease recurrence or progression during or after prior therapy that included: surgical resection, platinum agent, PARP inhibitor (for subjects with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer or as a maintenance therapy for subjects who have had complete or partial response to platinum-based therapy). P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort.
• NSCLC: Documented stage IIIB or IV or recurrent NSCLC, Disease recurrence or progression during or after prior treatment that included: platinum agent, targeted therapy such as a TKI (if with biopsy-confirmed cytogenetic mutation eg EGFR, ROS, BRAF). COM701 monotherapy expansion cohort.
• CRC (microsatellite stable, KRAS mutation) - P1b COM701 + nivolumab expansion cohort, COM701 monotherapy expansion cohort.
• For Phase 1a monotherapy expansion and Phase 1b only: subject has at least one measurable lesion that could be followed during the study according to RECIST v1.1.

Exclusion Criteria

• Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of COM701.
• Symptomatic interstitial lung disease or inflammatory pneumonitis.
• History of immune-related events that lead to immunotherapy treatment discontinuation.
• Untreated or symptomatic central nervous system (CNS) metastases.
• Impaired cardiac function or clinically significant cardiac disease, including any of the following: a) Unstable angina pectoris ≤ 6 months prior to first scheduled dose of COM701; b) Acute myocardial infarction ≤ 6 months prior to first scheduled dose of COM701.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Compugen Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

COM701 Study Director

Role: STUDY_DIRECTOR

Compugen USA, Inc.

Locations

University of California Los Angeles (UCLA).

Los Angeles, California, United States

Florida Cancer Specialists

Sarasota, Florida, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

START Midwest.

Grand Rapids, Michigan, United States

Columbia University

New York, New York, United States

Cleveland Clinic.

Cleveland, Ohio, United States

The University of Tennessee WEST Cancer Center.

Memphis, Tennessee, United States

Sarah Cannon Research Institute.

Nashville, Tennessee, United States

M D Anderson Cancer Center.

Houston, Texas, United States

The START Center for Cancer Care.

San Antonio, Texas, United States

Countries

United States

Other Identifiers

CPG-01-001

Identifier Type: -

Identifier Source: org_study_id